N
Neoplux
Private EquityActiveNeoplux operates as an investment arm of Doosan.
19
Investments
6
Exits
$1.2B
AUM
31.6%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Neoplux.
Investment Thesis & Strategy
Neoplux, as the investment arm of Doosan, invests in various stages across a broad range of industries, likely seeking companies that align with Doosan's strategic goals and potential synergies.
Investment Activity
Deals per year over the last 4 years
4
20142
20152
20162
2017Portfolio Companies
Selected investments from their portfolio of 19 companies
K
Kakaopay
Fintech · Growth, 2017
B
Bucketplace
Marketplaces · Series B, 2017
L
Lunit
Healthcare · Series A, 2016
M
Medipacto
Biotech · Series A, 2016
V
Viva Republica (Toss)
Fintech · Series B, 2015
R
Rsupport
Enterprise · Growth, 2015
Z
Zigbang
Real Estate · Series B, 2014
V
VCNC
Consumer · Series A, 2014
M
Memebox
E-commerce · Series B, 2014
W
Woowa Brothers
Food & Beverage · Series B, 2014
Notable Exits
CompanyTypeYearValue / Acquirer
L&C BioIPO2021—
GenomineAcquisition2021—
Woowa BrothersAcquisition2019$4B
HuonsIPO2011—
MedipostIPO2010—
CelltrionIPO2009—
Frequently Asked Questions
Neoplux focuses on Series B, Series C+ stage investments.